Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of 3BNC117-LS in HIV-infected and Uninfected Individuals
NCT03254277Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Sep 2017
- Primary completion
- Dec 2020
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Teropavimab in human immunodeficiency virus infection (HIV) (9 arms), sponsored by The Rockefeller University. Primary endpoints: Number of Participants Who Experience Adverse Events Within 2 Weeks After 3BNC117-LS Infusion and Elimination Half-life of 3BNC117-LS at 48 weeks. Started Sep 2017; status: completed.
02
Drugs
Teropavimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03254277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254277.